-

Thermo Fisher Scientific’s PPD Clinical Research Business Earns TOPRA Award for Regulatory Affairs Excellence in Supporting Novavax’s COVID-19 Vaccine Approval

WILMINGTON, N.C.--(BUSINESS WIRE)--The clinical research business of Thermo Fisher Scientific has won a 2021 TOPRA Award for Regulatory Excellence, recognizing the important role of its regulatory affairs team in expediting vaccine approvals during the COVID-19 global pandemic.

The TOPRA Award resulted from a nomination by Novavax, a Maryland-based biotechnology firm that has developed its own protein-based COVID-19 vaccine. Novavax made the nomination in the “support” category based on its ongoing clinical research organization (CRO) partnership with PPD, a leading global CRO that Thermo Fisher acquired in December 2021.

“The support PPD offered to our regulatory operations team has been integral to our success in working with regulatory authorities around the globe,” said Henrietta Ukwu, M.D., chief regulatory officer, Novavax, and winner of the TOPRA 2012 Inspirational Leadership Award. “PPD’s global footprint enabled timely, near simultaneous and successful submissions to many regulatory agencies leading to the major accomplishment of regulatory agencies’ authorizations for the Novavax COVID-19 vaccine around the globe.”

As part of its support for Novavax’s COVID-19 vaccine development program, PPD engaged with the appropriate regulatory authorities to expedite the review and approval of Novavax’ innovative COVID-19 vaccine.

“Our team worked tirelessly and seamlessly to guide Novavax through the procedures to ensure timely COVID-19 vaccine approval,” said Cindy Elko-Simms, M.D., senior vice president, pharmacovigilance, regulatory affairs and medical writing, clinical research, Thermo Fisher Scientific. “I am proud of our team for their expertise and professionalism, and we’re thankful to Novavax for their trust and close collaboration.”

TOPRA, a global organization for regulatory affairs professionals, promotes the profession by providing support, education and accreditation. Each year, the organization holds an awards competition for regulatory excellence, and all submissions are evaluated by an independent judging panel in the regulatory sector.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media:
Nadine Maeser
Phone: 919-456-4425
E-mail: Nadine.maeser@ppd.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Summary
The clinical research business of Thermo Fisher Scientific has won a 2021 TOPRA Award for Regulatory Excellence.
Release Versions

Contacts

Media:
Nadine Maeser
Phone: 919-456-4425
E-mail: Nadine.maeser@ppd.com

More News From Thermo Fisher

Thermo Fisher Scientific to Present at the J.P. Morgan 2026 Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the J.P. Morgan 2026 Healthcare Conference on Tuesday, January 13, 2026, at 11:15 a.m. (ET). A live webcast of the presentation will be available in the Investors section of our website, www.thermofisher.com, with a replay accessible shortly after the presentation concludes. About Thermo F...

Thermo Fisher Scientific Launches CorEvitas Obesity Registry to Advance Real-World Evidence in Treatment Outcomes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific launches CorEvitas Obesity Registry to advance real-world evidence in treatment outcomes....

Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, January 29, 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the fourth quarter and full year 2025 before the market opens on Thursday, January 29, 2026, and will hold a conference call on the same day at 8:30 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations. The call will be webcast live on the “Investors” section of our websit...
Back to Newsroom